id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
15729090_2 | We report a case of myoclonus induced by quetiapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[30]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"myoclonus\"]], \"start\": [[20]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"quetiapine\"]], \"start\": [[41]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"quetiapine\"]], \"start\": [[41]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[10]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
1393348_1 | A 21-year-old woman suffering from bipolar affective disorder developed systemic lupus erythematosus (SLE) with characteristic laboratory findings, 18 months after starting carbamazepine maintenance treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[62]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"A 21-year-old woman suffering from bipolar affective disorder\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"21-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[14]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"systemic lupus erythematosus (SLE)\"]], \"start\": [[72]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"18 months after starting carbamazepine maintenance treatment\"]], \"start\": [[148]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"bipolar affective disorder\"]], \"start\": [[35]], \"entity_id\": [\"T11\"]}, \"Time_elapsed\": {\"text\": [[\"18 months\"]], \"start\": [[148]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"carbamazepine\"]], \"start\": [[173]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
7973922_2 | Acyclovir produces neurologic symptoms that resemble extension of viral infection into the central nervous system. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"produces\"]], \"start\": [[10]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Acyclovir\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Acyclovir\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"neurologic symptoms\"]], \"start\": [[19]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
12086549_3 | Subcutaneous IL-2 is safe and well tolerated, with a mortality rate <3%. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[46]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Subcutaneous IL-2\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Route\": {\"text\": [[\"Subcutaneous\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"IL-2\"]], \"start\": [[13]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"mortality rate <3%\"]], \"start\": [[53]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
19434733_3 | Two patients with HLH developed etoposide-related secondary acute myeloid leukemia (sAML) following therapy for HLH. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[42]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"Two patients with HLH\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"Two\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"etoposide\"]], \"start\": [[32]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"HLH\"]], \"start\": [[18]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"etoposide\"]], \"start\": [[32]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"secondary acute myeloid leukemia (sAML)\"]], \"start\": [[50]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
2250853_2 | We report a case of secondary glaucoma caused by epithelial downgrowth in which filtration surgery was performed with adjunctive use of subconjunctival 5-fluorouracil. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[39]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"secondary glaucoma\", \"epithelial downgrowth\"]], \"start\": [[20, 49]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"filtration surgery was performed with adjunctive use of subconjunctival 5-fluorouracil\"]], \"start\": [[80]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"subconjunctival\"]], \"start\": [[136]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"5-fluorouracil\"]], \"start\": [[152]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
17189581_1 | Mild serotonin syndrome associated with concurrent linezolid and fluoxetine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[24]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"concurrent linezolid and fluoxetine\"]], \"start\": [[40]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"linezolid\"], [\"fluoxetine\"]], \"start\": [[51], [65]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[61]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"linezolid\"], [\"fluoxetine\"]], \"start\": [[51], [65]], \"entity_id\": [\"T9\", \"T10\"]}}]}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[5]], \"entity_id\": [\"T8\"]}, \"Severity\": {\"text\": [[\"Mild\"]], \"start\": [[0]], \"entity_id\": [\"T12\"], \"value\": \"Low\"}}"
}
]
}
] |
8530331_1 | Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[36]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Risperidone versus clozapine\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"Risperidone\"], [\"clozapine\"]], \"start\": [[0], [19]], \"entity_id\": [\"T14\", \"T15\"]}, \"Disorder\": {\"text\": [[\"psychosis\"]], \"start\": [[49]], \"entity_id\": [\"T1\"]}}, \"Subject\": {\"text\": [[\"six patients with Parkinson's disease and other akinetic-rigid syndromes\"]], \"start\": [[62]], \"entity_id\": [\"T10\"], \"Population\": {\"text\": [[\"six\"]], \"start\": [[62]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"Parkinson's disease\"], [\"akinetic-rigid syndromes\"]], \"start\": [[80], [110]], \"entity_id\": [\"T12\", \"T13\"]}}}"
}
]
}
] |
18691992_5 | Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[12]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Hydroxyurea\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Hydroxyurea\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas\"]], \"start\": [[28]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"an elderly subject\"]], \"start\": [[129]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[132]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
11889149_4 | Women (aged < or = 75 yr; > or = 2 yr since their last menstrual period) received placebo, RLX 60 mg/d, ALN 10 mg/d, or RLX 60 mg/d and ALN 10 mg/d combined. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"received\"]], \"start\": [[73]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"Women (aged < or = 75 yr; > or = 2 yr since their last menstrual period)\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"Gender\": {\"text\": [[\"Women\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}, \"Age\": {\"text\": [[\"aged < or = 75 yr; > or = 2 yr\"]], \"start\": [[7]], \"entity_id\": [\"T13\"]}}, \"Treatment\": {\"text\": [[\"RLX 60 mg/d, ALN 10 mg/d, or RLX 60 mg/d and ALN 10 mg/d combined\"]], \"start\": [[91]], \"entity_id\": [\"T10\"], \"Dosage\": {\"text\": [[\"60 mg/d\"], [\"10 mg/d\"], [\"60 mg/d\"], [\"10 mg/d\"]], \"start\": [[95], [108], [124], [140]], \"entity_id\": [\"T14\", \"T15\", \"T19\", \"T21\"]}, \"Drug\": {\"text\": [[\"RLX\"], [\"ALN\"], [\"RLX\"], [\"ALN\"]], \"start\": [[91], [104], [120], [136]], \"entity_id\": [\"T16\", \"T17\", \"T18\", \"T20\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combined\"]], \"start\": [[148]], \"entity_id\": [\"T22\"]}, \"Drug\": {\"text\": [[\"ALN\"], [\"RLX\"]], \"start\": [[136], [120]], \"entity_id\": [\"T20\", \"T18\"]}}]}}"
}
]
}
] |
8301877_2 | Myoclonus and seizures in a patient with parkinsonism: induction by levodopa and its confirmation on SEPs. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induction\"]], \"start\": [[55]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Myoclonus and seizures\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient with parkinsonism\"]], \"start\": [[26]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"levodopa\"]], \"start\": [[68]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"parkinsonism\"]], \"start\": [[41]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"levodopa\"]], \"start\": [[68]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
7663030_2 | OBJECTIVE: To describe a probable case of transient global amnesia caused by propafenone. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[67]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"transient global amnesia\"]], \"start\": [[42]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"propafenone\"]], \"start\": [[77]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"propafenone\"]], \"start\": [[77]], \"entity_id\": [\"T8\"]}}, \"Speculated\": {\"text\": [[\"probable\"]], \"start\": [[25]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
458006_2 | We report the development of squamous-cell carcinoma within a basal-cell epithelioma that was treated with intralesional injections of 5-FU. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[94]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"intralesional injections of 5-FU\"]], \"start\": [[107]], \"entity_id\": [\"T4\"], \"Route\": {\"text\": [[\"intralesional injections\"]], \"start\": [[107]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"5-FU\"]], \"start\": [[135]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"squamous-cell carcinoma within a basal-cell epithelioma\"]], \"start\": [[29]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
10745478_1 | This case report illustrates the use of continuous high-dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter in the treatment of a patient with cocaine-induced refractory coronary vasospasm. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[186]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"cocaine\"]], \"start\": [[178]], \"entity_id\": [\"T2\"], \"Drug\": {\"text\": [[\"cocaine\"]], \"start\": [[178]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"refractory coronary vasospasm\"]], \"start\": [[194]], \"entity_id\": [\"T3\"]}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[150]], \"entity_id\": [\"T1\"]}, \"Treatment\": {\"text\": [[\"use of continuous high-dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter\"]], \"start\": [[33]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"cocaine-induced refractory coronary vasospasm\"]], \"start\": [[178]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"intracoronary nitroglycerin\"]], \"start\": [[61]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"infusion through a 6 French coronary guiding catheter\"]], \"start\": [[89]], \"entity_id\": [\"T9\"]}, \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[51]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
18585545_3 | Here, we describe levofloxacin-induced delirium with psychotic features in a relatively young, otherwise healthy female. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[31]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"levofloxacin\"]], \"start\": [[18]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"levofloxacin\"]], \"start\": [[18]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"delirium with psychotic features\"]], \"start\": [[39]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"relatively young, otherwise healthy female\"]], \"start\": [[77]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
9876809_1 | Ticlopidine-induced phenytoin toxicity. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[12]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Ticlopidine\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Ticlopidine\"], [\"phenytoin\"]], \"start\": [[0], [20]], \"entity_id\": [\"T7\", \"T8\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"-\"]], \"start\": [[11]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"phenytoin\"], [\"Ticlopidine\"]], \"start\": [[20], [0]], \"entity_id\": [\"T8\", \"T7\"]}}]}, \"Effect\": {\"text\": [[\"toxicity\"]], \"start\": [[30]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
19540093_3 | Pancreatitis has been associated with the tetracycline class of antibiotics and concerns about tigecycline-induced acute pancreatitis have recently been raised. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[107]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"acute pancreatitis\"]], \"start\": [[115]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"tigecycline\"]], \"start\": [[95]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"tigecycline\"]], \"start\": [[95]], \"entity_id\": [\"T7\"]}}, \"Speculated\": {\"text\": [[\"concerns\"]], \"start\": [[80]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
2811895_1 | Abrupt, accidental withdrawal of trihexyphenidyl triggered severe exacerbation of the cranial dystonia associated with inspiratory stridor and acute respiratory difficulties, prompting emergency admission. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"triggered\"]], \"start\": [[49]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Abrupt, accidental withdrawal of trihexyphenidyl\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"trihexyphenidyl\"]], \"start\": [[33]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"exacerbation of the cranial dystonia associated with inspiratory stridor and acute respiratory difficulties\"]], \"start\": [[66]], \"entity_id\": [\"T9\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[59]], \"entity_id\": [\"T11\"], \"value\": \"High\"}}"
}
]
}
] |
3397227_2 | We report two patients with anhedonic ejaculation (ejaculation without orgasm) associated with initiation of treatment with desipramine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[79]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"two patients\"]], \"start\": [[10]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[10]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"desipramine\"]], \"start\": [[124]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"desipramine\"]], \"start\": [[124]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"anhedonic ejaculation (ejaculation without orgasm)\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
18191947_3 | We describe longitudinal diffusion-weighted MRI findings of sub-acute leukoencephalopathy following methotrexate therapy in a 24-year-old man diagnosed with pre-B-cell acute lymphoblastic leukemia (ALL), presenting with right-sided paralysis and aphasia after second consolidation with intrathecal triple-drug therapy given intrathecally. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[90]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"longitudinal diffusion-weighted MRI findings of sub-acute leukoencephalopathy\"]], \"start\": [[12]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"methotrexate\"]], \"start\": [[100]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[100]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"a 24-year-old man\"]], \"start\": [[124]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"24-year-old\"]], \"start\": [[126]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[138]], \"entity_id\": [\"T8\"]}}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[254]], \"entity_id\": [\"T1\"]}, \"Subject\": {\"text\": [[\"a 24-year-old man\"]], \"start\": [[124]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"24-year-old\"]], \"start\": [[126]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[138]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"second consolidation with intrathecal triple-drug therapy given intrathecally\"]], \"start\": [[260]], \"entity_id\": [\"T2\"], \"Disorder\": {\"text\": [[\"pre-B-cell acute lymphoblastic leukemia (ALL)\"]], \"start\": [[157]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"intrathecally\"]], \"start\": [[324]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"presenting with right-sided paralysis and aphasia\"]], \"start\": [[204]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
19915794_2 | Therefore, although garenoxacin reportedly causes fewer adverse reactions for cardiac rhythms than third-generation quinolone antibiotics, one must be cautious of the interference of other drugs during hypokalemia in order to prevent TdP. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"causes\"]], \"start\": [[43]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"garenoxacin\"]], \"start\": [[20]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"garenoxacin\"]], \"start\": [[20]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"adverse reactions for cardiac rhythms\"]], \"start\": [[56]], \"entity_id\": [\"T6\"]}, \"Negated\": {\"text\": [[\"fewer\"]], \"start\": [[50]], \"entity_id\": [\"T7\"], \"value\": true}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"prevent\"]], \"start\": [[226]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"garenoxacin\"]], \"start\": [[20]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"garenoxacin\"]], \"start\": [[20]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"hypokalemia\"]], \"start\": [[202]], \"entity_id\": [\"T15\"], \"Disorder\": {\"text\": [[\"hypokalemia\"]], \"start\": [[202]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"TdP\"]], \"start\": [[234]], \"entity_id\": [\"T13\"]}, \"Speculated\": {\"text\": [[\"cautious\"]], \"start\": [[151]], \"entity_id\": [\"T16\"], \"value\": true}}"
}
]
}
] |
12792223_1 | A 45-year-old woman with steroid-dependent Crohn's colitis, successfully managed with maintenance infliximab infusions and methotrexate, developed a lupus-like syndrome eight months after her initial infusion. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[137]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"A 45-year-old woman with steroid-dependent Crohn's colitis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"45-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[14]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"lupus-like syndrome\"]], \"start\": [[149]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"maintenance infliximab infusions and methotrexate\", \"eight months after her initial infusion\"]], \"start\": [[86, 169]], \"entity_id\": [\"T5\"], \"Time_elapsed\": {\"text\": [[\"eight months\"]], \"start\": [[169]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"infliximab\"], [\"methotrexate\"]], \"start\": [[98], [123]], \"entity_id\": [\"T12\", \"T14\"]}, \"Route\": {\"text\": [[\"infusions\"]], \"start\": [[109]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"steroid-dependent Crohn's colitis\"]], \"start\": [[25]], \"entity_id\": [\"T16\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[119]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"infliximab\"], [\"methotrexate\"]], \"start\": [[98], [123]], \"entity_id\": [\"T12\", \"T14\"]}}]}}"
}
]
}
] |
6292681_1 | Severe neurotoxicity with methyl G: CALGB experience. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"neurotoxicity\"]], \"start\": [[7]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"methyl G\"]], \"start\": [[26]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"methyl G\"]], \"start\": [[26]], \"entity_id\": [\"T6\"]}}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"value\": \"High\"}}"
}
]
}
] |
3725284_2 | We report a case of a 60-year-old woman affected by squamous lung carcinoma, who developed paroxysmal supraventricular tachycardia during cisplatin and etoposide combination chemotherapy. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[81]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"60-year-old woman affected by squamous lung carcinoma\"]], \"start\": [[22]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"60-year-old\"]], \"start\": [[22]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[34]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"paroxysmal supraventricular tachycardia\"]], \"start\": [[91]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"cisplatin and etoposide combination\"]], \"start\": [[138]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"cisplatin\"], [\"etoposide\"]], \"start\": [[138], [152]], \"entity_id\": [\"T11\", \"T12\"]}, \"Disorder\": {\"text\": [[\"squamous lung carcinoma,\"]], \"start\": [[52]], \"entity_id\": [\"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[162]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"etoposide\"], [\"cisplatin\"]], \"start\": [[152], [138]], \"entity_id\": [\"T12\", \"T11\"]}}]}}"
}
]
}
] |
9177620_2 | The authors report a case of acute pancreatitis (AP) occurring in a patient under treatment with carbamazepine (CBZ) for post-traumatic petit mal epilepsy, and review the current literature of drug-induced AP. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurring\"]], \"start\": [[53]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"acute pancreatitis\"]], \"start\": [[29]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"carbamazepine\"]], \"start\": [[97]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"post-traumatic petit mal epilepsy\"]], \"start\": [[121]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"carbamazepine\"]], \"start\": [[97]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[66]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
19707032_1 | Acute ocular ischemic change may be associated with intravitreal injection of bevacizumab in patients with vascular compromised diabetic retinopathy and/or underlying stenosis of the carotid artery. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[36]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Acute ocular ischemic change\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"intravitreal injection of bevacizumab\"]], \"start\": [[52]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"bevacizumab\"]], \"start\": [[78]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"intravitreal injection\"]], \"start\": [[52]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"patients with vascular compromised diabetic retinopathy and/or underlying stenosis of the carotid artery\"]], \"start\": [[93]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"vascular compromised diabetic retinopathy\"], [\"underlying stenosis of the carotid artery\"]], \"start\": [[107], [156]], \"entity_id\": [\"T7\", \"T1\"]}}}"
}
]
}
] |
17852449_2 | All-trans-retinoic acid (ATRA) has been proved to be an effective treatment for acute promyelocytic leukemia (APL), inducing remission in more than 90% of cases. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"proved\"]], \"start\": [[40]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"All-trans-retinoic acid (ATRA)\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"acute promyelocytic leukemia (APL)\"]], \"start\": [[80]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"All-trans-retinoic acid\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"more than 90% of cases\"]], \"start\": [[138]], \"entity_id\": [\"T9\"], \"Population\": {\"text\": [[\"more than 90%\"]], \"start\": [[138]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
18698687_2 | Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[49]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Vanishing bile duct and Stevens-Johnson syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"ciprofloxacin\"]], \"start\": [[65]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"ciprofloxacin\"]], \"start\": [[65]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
9161656_5 | Antiasthmatic medications were prescribed, but the asthma symptoms did not improve. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"improve\"]], \"start\": [[75]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Antiasthmatic medications were prescribed\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"asthma\"]], \"start\": [[51]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"Antiasthmatic medications\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Negated\": {\"text\": [[\"not\"]], \"start\": [[71]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
12590235_1 | Both 6-MP and AZA are widely used and are known to cause hepatotoxicity in a proportion of patients. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"used\"]], \"start\": [[29]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a proportion of patients\"]], \"start\": [[75]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"6-MP and AZA\"]], \"start\": [[5]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"AZA\"], [\"6-MP\"]], \"start\": [[14], [5]], \"entity_id\": [\"T8\", \"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[10]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"6-MP\"], [\"AZA\"]], \"start\": [[5], [14]], \"entity_id\": [\"T9\", \"T8\"]}}]}, \"Effect\": {\"text\": [[\"hepatotoxicity\"]], \"start\": [[57]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
11889149_2 | Both raloxifene (RLX) and alendronate (ALN) can treat and prevent new vertebral fractures, increase bone mineral density (BMD), and decrease biochemical markers of bone turnover in postmenopausal women with osteoporosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treat\"]], \"start\": [[48]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"Both raloxifene (RLX) and alendronate (ALN)\"]], \"start\": [[0]], \"entity_id\": [\"T13\"], \"Disorder\": {\"text\": [[\"vertebral fractures\"]], \"start\": [[70]], \"entity_id\": [\"T19\"]}, \"Drug\": {\"text\": [[\"raloxifene\"], [\"alendronate\"]], \"start\": [[5], [26]], \"entity_id\": [\"T15\", \"T18\"]}}, \"Subject\": {\"text\": [[\"postmenopausal women with osteoporosis\"]], \"start\": [[181]], \"entity_id\": [\"T17\"], \"Disorder\": {\"text\": [[\"osteoporosis\"]], \"start\": [[207]], \"entity_id\": [\"T16\"]}}, \"Effect\": {\"text\": [[\"increase bone mineral density (BMD)\"], [\"decrease biochemical markers of bone turnover\"]], \"start\": [[91], [132]], \"entity_id\": [\"T1\", \"T2\"]}}"
}
]
}
] |
9840249_3 | We report a case of severe respiratory failure due to gold salt toxicity in a patient suffering from rheumatoid arthritis requiring mechanical ventilation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[47]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"respiratory failure\"]], \"start\": [[27]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"gold salt\"]], \"start\": [[54]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"]], \"start\": [[101]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"gold\"]], \"start\": [[54]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"a patient suffering from rheumatoid arthritis\"]], \"start\": [[76]], \"entity_id\": [\"T5\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[20]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
3628148_2 | We describe rupture of a cerebral arterial aneurysm in a 32 year old hypertensive woman following the introduction of nifedipine treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[88]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"rupture of a cerebral arterial aneurysm\"]], \"start\": [[12]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a 32 year old hypertensive woman\"]], \"start\": [[55]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"32 year old\"]], \"start\": [[57]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[82]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"nifedipine treatment\"]], \"start\": [[118]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"hypertensive\"]], \"start\": [[69]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"nifedipine\"]], \"start\": [[118]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
16882109_2 | Factors that suggested an association between the severe angioedematous reaction and BP topical application include the strong reaction to BP in the patch-test, the temporal relationship, the complete resolution of symptoms after the drug was withdrawn and the absence of other identified explanations. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"association\"]], \"start\": [[26]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"severe angioedematous reaction\"]], \"start\": [[50]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"BP topical application\"]], \"start\": [[85]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"BP topical application\"]], \"start\": [[85]], \"entity_id\": [\"T8\"]}}, \"Speculated\": {\"text\": [[\"suggested\"]], \"start\": [[13]], \"entity_id\": [\"T5\"], \"value\": true}}"
}
]
}
] |
11889149_14 | RLX+ALN reduced bone turnover more than either drug alone, resulting in greater BMD increment, but whether this difference reflects better fracture risk reduction was not assessed in this study. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"reduced\"]], \"start\": [[8]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"RLX\"], [\"ALN\"]], \"start\": [[0], [4]], \"entity_id\": [\"T7\", \"T8\"], \"Drug\": {\"text\": [[\"RLX\"], [\"ALN\"]], \"start\": [[0], [4]], \"entity_id\": [\"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"+\"]], \"start\": [[3]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"RLX\"], [\"ALN\"]], \"start\": [[0], [4]], \"entity_id\": [\"T12\", \"T13\"]}}]}, \"Effect\": {\"text\": [[\"bone turnover more than either drug alone, resulting in greater BMD increment\"]], \"start\": [[16]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
11881322_3 | Hepatotoxicity related to itraconazole: report of three cases. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[15]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"itraconazole\"]], \"start\": [[26]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"itraconazole\"]], \"start\": [[26]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"Hepatotoxicity\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"three cases\"]], \"start\": [[50]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"three\"]], \"start\": [[50]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
2295443_3 | This report presents a case of colon perforation which occurred 4 months after treatment with intraperitoneal chromic phosphate for stage IB ovarian papillary serous cystadenocarcinoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[55]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"colon perforation\"]], \"start\": [[31]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"intraperitoneal chromic phosphate\"]], \"start\": [[94]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"chromic phosphate\"]], \"start\": [[110]], \"entity_id\": [\"T7\"]}, \"Time_elapsed\": {\"text\": [[\"4 months\"]], \"start\": [[64]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"intraperitoneal\"]], \"start\": [[94]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"stage IB ovarian papillary serous cystadenocarcinoma\"]], \"start\": [[132]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
9634122_1 | Flutamide withdrawal syndrome is characterized by a decrease in prostate-specific antigen (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"withdrawal\"]], \"start\": [[112]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"flutamide\"]], \"start\": [[102]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"progressing metastatic carcinoma of the prostate\"]], \"start\": [[152]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"flutamide\"]], \"start\": [[102]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"decrease in prostate-specific antigen (PSA)\"]], \"start\": [[52]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"subset of patients with progressing metastatic carcinoma of the prostate\"]], \"start\": [[128]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
7282702_2 | Bradycardia and congestive heart failure associated with ocular timolol maleate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[41]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Bradycardia and congestive heart failure\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"ocular timolol maleate\"]], \"start\": [[57]], \"entity_id\": [\"T7\"], \"Route\": {\"text\": [[\"ocular\"]], \"start\": [[57]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"timolol maleate\"]], \"start\": [[64]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
19707032_4 | CONCLUSIONS: Patients receiving intravitreal injections of bevacizumab should be evaluated for potential systemic risk factors such as carotid insufficiency, coagulopathy and poorly controlled diabetes mellitus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"risk\"]], \"start\": [[114]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"carotid insufficiency, coagulopathy and poorly controlled diabetes mellitus\"]], \"start\": [[135]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"intravitreal injections of bevacizumab\"]], \"start\": [[32]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"bevacizumab\"]], \"start\": [[59]], \"entity_id\": [\"T10\"]}, \"Route\": {\"text\": [[\"intravitreal injections\"]], \"start\": [[32]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
25671244_13 | Severe serotonin toxicity may result from metaxalone abuse in individuals using a selective serotonin reuptake inhibitor therapeutically. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"result\"]], \"start\": [[30]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"serotonin toxicity\"]], \"start\": [[7]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"metaxalone abuse\", \"using a selective serotonin reuptake inhibitor therapeutically\"]], \"start\": [[42, 74]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"metaxalone\"], [\"selective serotonin reuptake inhibitor\"]], \"start\": [[42], [82]], \"entity_id\": [\"T9\", \"T11\"]}, \"Dosage\": {\"text\": [[\"abuse\"]], \"start\": [[53]], \"entity_id\": [\"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"using\"]], \"start\": [[74]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"metaxalone\"], [\"selective serotonin reuptake inhibitor\"]], \"start\": [[42], [82]], \"entity_id\": [\"T9\", \"T11\"]}}]}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[0]], \"entity_id\": [\"T13\"], \"value\": \"High\"}}"
}
]
}
] |
18504683_2 | The purpose of this article is to present the first case-series of posterior reversible encephalopathy syndrome (PRES) associated with L-asparaginase treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[119]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"L-asparaginase treatment\"]], \"start\": [[135]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"L-asparaginase\"]], \"start\": [[135]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"posterior reversible encephalopathy syndrome (PRES)\"]], \"start\": [[67]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
16029707_1 | Eruptive epidermoid cysts resulting from treatment with imiquimod. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulting\"]], \"start\": [[26]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"imiquimod\"]], \"start\": [[56]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"imiquimod\"]], \"start\": [[56]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Eruptive epidermoid cysts\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
12757344_1 | Carbamazepine-related hyponatremia following cardiopulmonary bypass. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Carbamazepine\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Carbamazepine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hyponatremia\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
15379082_2 | Fulminant hepatic failure is a rare complication of disulfiram treatment for alcoholism. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[36]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Fulminant hepatic failure\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"disulfiram\"]], \"start\": [[52]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"alcoholism\"]], \"start\": [[77]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"disulfiram\"]], \"start\": [[52]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
11049910_11 | Implications: Clinicians should be aware of the possibility of increased toxicity of ropivacaine when used together with inhibitors of CYP1A2. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"increased\"]], \"start\": [[63]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"ropivacaine\"], [\"inhibitors of CYP1A2\"]], \"start\": [[85], [121]], \"entity_id\": [\"T7\", \"T10\"], \"Drug\": {\"text\": [[\"ropivacaine\"], [\"inhibitors of CYP1A2\"]], \"start\": [[85], [121]], \"entity_id\": [\"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"together with\"]], \"start\": [[107]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"inhibitors of CYP1A2\"], [\"ropivacaine\"]], \"start\": [[121], [85]], \"entity_id\": [\"T12\", \"T11\"]}}]}, \"Effect\": {\"text\": [[\"toxicity\"]], \"start\": [[73]], \"entity_id\": [\"T9\"]}, \"Speculated\": {\"text\": [[\"possibility\"]], \"start\": [[48]], \"entity_id\": [\"T14\"], \"value\": true}}"
}
]
}
] |
3379435_1 | Evidence obtained indicated that the Reye-like syndrome might be caused by calcium hopantenate possibly due to the induction of pantothenic acid deficiency. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[65]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Reye-like syndrome\"]], \"start\": [[37]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"calcium hopantenate\"]], \"start\": [[75]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"calcium hopantenate\"]], \"start\": [[75]], \"entity_id\": [\"T8\"]}}, \"Speculated\": {\"text\": [[\"might\"]], \"start\": [[56]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
3143551_5 | Hepatopathy subsided after the cessation of carbamazepine and lynestrenol. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"carbamazepine\", \"lynestrenol\"]], \"start\": [[44, 62]], \"entity_id\": [\"T4\"], \"Dosage\": {\"text\": [[\"cessation\"]], \"start\": [[31]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"carbamazepine\"], [\"lynestrenol\"]], \"start\": [[44], [62]], \"entity_id\": [\"T8\", \"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[58]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"lynestrenol\"], [\"carbamazepine\"]], \"start\": [[62], [44]], \"entity_id\": [\"T9\", \"T8\"]}}]}, \"Effect\": {\"text\": [[\"Hepatopathy subsided\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
8667442_2 | This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulting\"]], \"start\": [[110]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"calcium carbonate and calcitriol\"]], \"start\": [[77]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"hypoparathyroidism\"]], \"start\": [[37]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"calcium carbonate\"], [\"calcitriol\"]], \"start\": [[77], [99]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[95]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"calcium carbonate\"], [\"calcitriol\"]], \"start\": [[77], [99]], \"entity_id\": [\"T9\", \"T10\"]}}]}, \"Effect\": {\"text\": [[\"two admissions to the hospital for milk-alkali syndrome\"]], \"start\": [[123]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a patient with hypoparathyroidism\"]], \"start\": [[22]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
16997047_3 | Recurrent hyponatremia associated with citalopram and mirtazapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[23]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Recurrent hyponatremia\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"citalopram and mirtazapine\"]], \"start\": [[39]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"citalopram\"], [\"mirtazapine\"]], \"start\": [[39], [54]], \"entity_id\": [\"T7\", \"T8\"]}}}"
}
]
}
] |
24429012_2 | A case report of a sharp rise in International Normalized Ratio (INR) values during a patient's concomitant use of warfarin and the antineoplastic agent vismodegib is presented. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[77]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"a sharp rise in International Normalized Ratio (INR) values\"]], \"start\": [[17]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[84]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"concomitant use of warfarin and the antineoplastic agent vismodegib\"]], \"start\": [[96]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"warfarin\"], [\"vismodegib\"]], \"start\": [[115], [153]], \"entity_id\": [\"T13\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"concomitant\"]], \"start\": [[96]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"warfarin\"], [\"vismodegib\"]], \"start\": [[115], [153]], \"entity_id\": [\"T13\", \"T14\"]}}]}}"
}
]
}
] |
18810448_1 | In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true thymic hyperplasia), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under Etanercept treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[80]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"a case of juvenile idiopathic arthritis patient\"]], \"start\": [[28]], \"entity_id\": [\"T9\"], \"Age\": {\"text\": [[\"juvenile\"]], \"start\": [[38]], \"entity_id\": [\"T1\"]}}, \"Effect\": {\"text\": [[\"thymic enlargement (true thymic hyperplasia), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms\"]], \"start\": [[90]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"Etanercept\"]], \"start\": [[217]], \"entity_id\": [\"T13\"], \"Disorder\": {\"text\": [[\"idiopathic arthritis\"]], \"start\": [[47]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"Etanercept\"]], \"start\": [[217]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
2445709_1 | A 52-year-old woman developed symmetric sensorimotor polyneuropathy and cerebellar syndrome after 24 months of amiodarone treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[20]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"A 52-year-old woman\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"52-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[14]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"symmetric sensorimotor polyneuropathy\", \"cerebellar syndrome\"]], \"start\": [[30, 72]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"amiodarone\"]], \"start\": [[111]], \"entity_id\": [\"T8\"], \"Time_elapsed\": {\"text\": [[\"24 months\"]], \"start\": [[98]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[111]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
18396749_3 | The case of a patient under tibolone therapy for two years who developed a mixed-type liver injury with prolonged cholestasis and features of the vanishing bile duct syndrome following a ten weeks treatment with St. John wort (Hypericum Perforatum) infusions is reported. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[63]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"under tibolone therapy\", \"a ten weeks treatment with St. John wort (Hypericum Perforatum) infusions\"]], \"start\": [[22, 185]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Hypericum Perforatum\"], [\"tibolone\"]], \"start\": [[227], [28]], \"entity_id\": [\"T10\", \"T13\"]}, \"Route\": {\"text\": [[\"infusions\"]], \"start\": [[249]], \"entity_id\": [\"T11\"]}, \"Duration\": {\"text\": [[\"ten weeks\"]], \"start\": [[187]], \"entity_id\": [\"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[175]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"tibolone\"], [\"Hypericum Perforatum\"]], \"start\": [[28], [227]], \"entity_id\": [\"T13\", \"T10\"]}}]}, \"Subject\": {\"text\": [[\"a patient under tibolone therapy\"]], \"start\": [[12]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"a mixed-type liver injury with prolonged cholestasis and features of the vanishing bile duct syndrome\"]], \"start\": [[73]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
18094347_6 | OBJECTIVE: To report a case of a diffuse papular eruption following treatment of psoriasis with methotrexate injections. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[58]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"diffuse papular eruption\"]], \"start\": [[33]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"methotrexate injections\"]], \"start\": [[96]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[96]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"injections\"]], \"start\": [[109]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"psoriasis\"]], \"start\": [[81]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
10099659_1 | Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[32]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"5-fluorouracil\"]], \"start\": [[17]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"5-fluorouracil\"]], \"start\": [[17]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"dihydropyrimidine dehydrogenase deficiency\"]], \"start\": [[75]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"a patient with dihydropyrimidine dehydrogenase deficiency\"]], \"start\": [[60]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"neurotoxicity\"]], \"start\": [[43]], \"entity_id\": [\"T12\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[10]], \"entity_id\": [\"T14\"], \"value\": \"High\"}}"
}
]
}
] |
18343993_3 | Life-threatening interstitial lung disease associated with trastuzumab: case report. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[43]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"trastuzumab\"]], \"start\": [[59]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"trastuzumab\"]], \"start\": [[59]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Life-threatening interstitial lung disease\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"case\"]], \"start\": [[72]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
15694139_6 | Thalidomide neuropathy is often associated with proximal weakness and may progress even after discontinuation of treatment, in the phenomenon of 'coasting'. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[32]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"neuropathy\", \"proximal weakness\"]], \"start\": [[12, 48]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Thalidomide\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Thalidomide\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Speculated\": {\"text\": [[\"often\"]], \"start\": [[26]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
18607107_3 | RESULTS: Our patient developed Crohn's disease while on Copaxone treatment as a consequence of long-term immunosuppression. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Crohn's disease\", \"long-term immunosuppression\"]], \"start\": [[31, 95]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[13]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Copaxone\"]], \"start\": [[56]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"Copaxone\"]], \"start\": [[56]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
19707032_2 | Acute vision loss after intravitreal injection of bevacizumab (avastin) associated with ocular ischemic syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[18]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Acute vision loss\"], [\"ocular ischemic syndrome\"]], \"start\": [[0], [88]], \"entity_id\": [\"T7\", \"T10\"]}, \"Treatment\": {\"text\": [[\"intravitreal injection of bevacizumab (avastin)\"]], \"start\": [[24]], \"entity_id\": [\"T9\"], \"Route\": {\"text\": [[\"intravitreal injection\"]], \"start\": [[24]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"bevacizumab\"]], \"start\": [[50]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
2663536_1 | Development of persistent late onset asthma following treatment with captopril. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[44]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"captopril\"]], \"start\": [[69]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"captopril\"]], \"start\": [[69]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"persistent late onset asthma\"]], \"start\": [[15]], \"entity_id\": [\"T5\"]}, \"Severity\": {\"text\": [[\"persistent\"]], \"start\": [[15]], \"entity_id\": [\"T6\"], \"value\": \"High\"}}"
}
]
}
] |
19717383_1 | Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[44]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"a patient with AIDS\"]], \"start\": [[20]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"AIDS\"]], \"start\": [[35]], \"entity_id\": [\"T13\"]}}, \"Treatment\": {\"text\": [[\"48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH)\"]], \"start\": [[93]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"diffuse large B-cell lymphoma\"]], \"start\": [[220]], \"entity_id\": [\"T10\"]}, \"Duration\": {\"text\": [[\"48 months\"]], \"start\": [[93]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"etoposide\"], [\"prednisone\"], [\"vincristine\"], [\"cyclophosphamide\"], [\"doxorubicin\"], [\"rituximab\"]], \"start\": [[125], [136], [148], [161], [179], [196]], \"entity_id\": [\"T16\", \"T17\", \"T18\", \"T19\", \"T20\", \"T21\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[192]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"etoposide\"], [\"prednisone\"], [\"vincristine\"], [\"cyclophosphamide\"], [\"doxorubicin\"], [\"rituximab\"]], \"start\": [[125], [136], [148], [161], [179], [196]], \"entity_id\": [\"T16\", \"T17\", \"T18\", \"T19\", \"T20\", \"T21\"]}}]}, \"Effect\": {\"text\": [[\"medical attention with pancytopenia\"]], \"start\": [[57]], \"entity_id\": [\"T12\"]}}"
}
]
}
] |
8038468_2 | However, prolongation of 5-FU half-life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reported\"]], \"start\": [[73]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"prolongation of 5-FU half-life and an increase in INR\"]], \"start\": [[9]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"the concurrent use of 5-FU and warfarin\"]], \"start\": [[87]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"warfarin\"], [\"5-FU\"]], \"start\": [[118], [109]], \"entity_id\": [\"T7\", \"T8\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"concurrent\"]], \"start\": [[91]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"5-FU\"], [\"warfarin\"]], \"start\": [[109], [118]], \"entity_id\": [\"T8\", \"T7\"]}}]}}"
}
]
}
] |
7718983_1 | Graves' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[59]], \"entity_id\": [\"T14\"]}, \"Effect\": {\"text\": [[\"Graves' hyperthyroidism following transient thyrotoxicosis\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"interferon\"]], \"start\": [[66]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"interferon\"]], \"start\": [[66]], \"entity_id\": [\"T15\"]}, \"Disorder\": {\"text\": [[\"chronic hepatitis type C\"]], \"start\": [[89]], \"entity_id\": [\"T16\"]}}}"
}
]
}
] |
17083900_2 | We report a case of acute generalized exanthematous pustulosis (AGEP) in a 50-year-old woman that was attributed to the ingestion of nimesulide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"attributed\"]], \"start\": [[102]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"acute generalized exanthematous pustulosis (AGEP)\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a 50-year-old woman\"]], \"start\": [[73]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"50-year-old\"]], \"start\": [[75]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[87]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"ingestion of nimesulide\"]], \"start\": [[120]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"nimesulide\"]], \"start\": [[133]], \"entity_id\": [\"T11\"]}, \"Route\": {\"text\": [[\"ingestion\"]], \"start\": [[120]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
18191947_2 | This case demonstrates the value of DWI in evaluation and diagnosis of sub-acute toxic leukoencephalopathy in patients being treated with methotrexate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[107]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"sub-acute toxic leukoencephalopathy\"]], \"start\": [[71]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"methotrexate\"]], \"start\": [[138]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[138]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[110]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
15785053_3 | We report the first histopathologically documented case of oral mucosa pigmentation after OLP treatment with topical tacrolimus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[94]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"topical tacrolimus\"]], \"start\": [[109]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"tacrolimus\"]], \"start\": [[117]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"OLP\"]], \"start\": [[90]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"topical\"]], \"start\": [[109]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"oral mucosa pigmentation\"]], \"start\": [[59]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
16298824_5 | Progressive hypoxemia mandated endotracheal intubation 1 week after rituximab administration and led to death 4 weeks after admission. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[62]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Progressive hypoxemia\", \"led to death\"]], \"start\": [[0, 97]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"rituximab administration\"]], \"start\": [[68]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"rituximab\"]], \"start\": [[68]], \"entity_id\": [\"T6\"]}, \"Time_elapsed\": {\"text\": [[\"1 week\"]], \"start\": [[55]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
21751542_4 | Angiotensin converting enzyme blockers and their influence on the endothelial dysfunction, but the risk of hyperpotassemia are showed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"showed\"]], \"start\": [[127]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Angiotensin converting enzyme blockers\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"Angiotensin converting enzyme blockers\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"hyperpotassemia\"]], \"start\": [[107]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"risk\"]], \"start\": [[99]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
24846936_2 | This is the first report of a fatal outcome from serotonin toxicity, precipitated by an interaction between methylene blue and venlafaxine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"precipitated\"]], \"start\": [[69]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"methylene blue\", \"venlafaxine\"]], \"start\": [[108, 127]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"methylene blue\"], [\"venlafaxine\"]], \"start\": [[108], [127]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[88]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"methylene blue\"], [\"venlafaxine\"]], \"start\": [[108], [127]], \"entity_id\": [\"T9\", \"T10\"]}}]}, \"Effect\": {\"text\": [[\"serotonin toxicity\"]], \"start\": [[49]], \"entity_id\": [\"T8\"]}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[30]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
19904536_10 | A helicoidal CT scan showed diffuse and severe interstitial pneumonitis, and lung biopsy confirmed accelerated usual interstitial pneumonia consistent with drug-induced toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[161]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"diffuse and severe interstitial pneumonitis\", \"accelerated usual interstitial pneumonia\", \"toxicity\"]], \"start\": [[28, 99, 169]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"drug\"]], \"start\": [[156]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"drug\"]], \"start\": [[156]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
10614572_3 | We report a case of severe hypotension associated with intravenous valproate used to treat status epilepticus in an 11-year-old girl. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[39]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"intravenous valproate\"]], \"start\": [[55]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"status epilepticus\"]], \"start\": [[91]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[55]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"valproate\"]], \"start\": [[67]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"hypotension\"]], \"start\": [[27]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"an 11-year-old girl\"]], \"start\": [[113]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"11-year-old\"]], \"start\": [[116]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"girl\"]], \"start\": [[128]], \"entity_id\": [\"T9\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[20]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
11489400_1 | Relief by naloxone of morphine-induced spasm of the sphincter of Oddi in a post-cholecystectomy patient. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"Relief\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"naloxone\"]], \"start\": [[10]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"morphine-induced spasm of the sphincter of Oddi\"]], \"start\": [[22]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"naloxone\"]], \"start\": [[10]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"post-cholecystectomy patient.\"]], \"start\": [[75]], \"entity_id\": [\"T4\"]}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[31]], \"entity_id\": [\"T1\"]}, \"Subject\": {\"text\": [[\"post-cholecystectomy patient.\"]], \"start\": [[75]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"morphine\"]], \"start\": [[22]], \"entity_id\": [\"T2\"], \"Drug\": {\"text\": [[\"morphine\"]], \"start\": [[22]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"spasm of the sphincter of Oddi\"]], \"start\": [[39]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
17610180_2 | The results of the ultrasound examination combined with clinical anamnesis allowed diagnosis of gastric mucosa foveolar hyperplasia due to prolonged PGE1 therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[132]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"prolonged PGE1 therapy\"]], \"start\": [[139]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"PGE1\"]], \"start\": [[149]], \"entity_id\": [\"T6\"]}, \"Duration\": {\"text\": [[\"prolonged\"]], \"start\": [[139]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"gastric mucosa foveolar hyperplasia\"]], \"start\": [[96]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
6683487_4 | To our knowledge, no prior cases of penicillamine-induced TTP in RA have been reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[50]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"penicillamine\"]], \"start\": [[36]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"penicillamine\"]], \"start\": [[36]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"TTP\"]], \"start\": [[58]], \"entity_id\": [\"T8\"]}, \"Negated\": {\"text\": [[\"no\"]], \"start\": [[18]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
6529939_1 | Alternating sinus rhythm and intermittent sinoatrial block induced by propranolol. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[59]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Alternating sinus rhythm and intermittent sinoatrial block\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"propranolol\"]], \"start\": [[70]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"propranolol\"]], \"start\": [[70]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
9701106_5 | The noted increase in the theophylline level after zafirlukast administration is in contrast to the original reports by the manufacturer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[45]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"increase in the theophylline level\"]], \"start\": [[10]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"zafirlukast administration\"]], \"start\": [[51]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"zafirlukast\"]], \"start\": [[51]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
6947095_2 | The cause is presumed to be secondary to hypercoagulability due to asparaginase-induced antithrombin III deficiency. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[80]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"antithrombin III deficiency\"]], \"start\": [[88]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"asparaginase\"]], \"start\": [[67]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"asparaginase\"]], \"start\": [[67]], \"entity_id\": [\"T7\"]}}, \"Speculated\": {\"text\": [[\"presumed\"]], \"start\": [[13]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
10749332_5 | Troglitazone-induced fulminant hepatic failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[13]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Troglitazone\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Troglitazone\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"fulminant hepatic failure\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
2320800_2 | A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[87]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"Age\": {\"text\": [[\"sixty-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T13\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[17]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"an irreversible lethal renal failure with anuria\"]], \"start\": [[97]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"the day after 5 g/m2 bolus ifosfamide\"]], \"start\": [[147]], \"entity_id\": [\"T12\"], \"Disorder\": {\"text\": [[\"advanced breast cancer\"]], \"start\": [[28]], \"entity_id\": [\"T15\"]}, \"Time_elapsed\": {\"text\": [[\"the day after\"]], \"start\": [[147]], \"entity_id\": [\"T17\"]}, \"Dosage\": {\"text\": [[\"5 g/m2\"]], \"start\": [[161]], \"entity_id\": [\"T18\"]}, \"Drug\": {\"text\": [[\"ifosfamide\"]], \"start\": [[174]], \"entity_id\": [\"T19\"]}}, \"Severity\": {\"text\": [[\"irreversible\"]], \"start\": [[100]], \"entity_id\": [\"T20\"], \"value\": \"High\"}}"
}
]
}
] |
10467499_2 | With the negative viral serologies, the clinical picture was most consistent with an infectious mononucleosis-like syndrome produced by the minocycline ingestion. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"produced\"]], \"start\": [[124]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"minocycline ingestion\"]], \"start\": [[140]], \"entity_id\": [\"T3\"], \"Route\": {\"text\": [[\"ingestion\"]], \"start\": [[152]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"minocycline\"]], \"start\": [[140]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"infectious mononucleosis-like syndrome\"]], \"start\": [[85]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
15920338_2 | High-grade endometrial stromal sarcoma after tamoxifen therapy for breast cancer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[39]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"High-grade endometrial stromal sarcoma\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"tamoxifen\"]], \"start\": [[45]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"tamoxifen\"]], \"start\": [[45]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"breast cancer\"]], \"start\": [[67]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
16207263_2 | We report here two cases of dyserythropoietic anaemia associated with long-term linezolid use that share striking similarities to chloramphenicol-associated myelotoxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[54]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"dyserythropoietic anaemia\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"long-term linezolid\"]], \"start\": [[70]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"linezolid\"]], \"start\": [[80]], \"entity_id\": [\"T8\"]}, \"Duration\": {\"text\": [[\"long-term\"]], \"start\": [[70]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
16503727_2 | Dipyrone-induced granulocytopenia: a case for awareness. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[9]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Dipyrone\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Dipyrone\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"granulocytopenia\"]], \"start\": [[17]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[35]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
22233409_4 | We report the case of a patient with chronic hepatitis C infection who developed severe anaemia during antiviral treatment with peginterferon alfa/ribavirin when oseltamivir was added to treat influenza. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[71]], \"entity_id\": [\"T15\"]}, \"Effect\": {\"text\": [[\"severe anaemia\"]], \"start\": [[81]], \"entity_id\": [\"T16\"]}, \"Treatment\": {\"text\": [[\"peginterferon alfa/ribavirin\", \"oseltamivir\"]], \"start\": [[128, 162]], \"entity_id\": [\"T17\"], \"Disorder\": {\"text\": [[\"chronic hepatitis C infection\"], [\"influenza\"]], \"start\": [[37], [193]], \"entity_id\": [\"T14\", \"T18\"]}, \"Drug\": {\"text\": [[\"peginterferon alfa\"], [\"ribavirin\"], [\"oseltamivir\"]], \"start\": [[128], [147], [162]], \"entity_id\": [\"T19\", \"T20\", \"T22\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"/\"]], \"start\": [[146]], \"entity_id\": [\"T21\"]}, \"Drug\": {\"text\": [[\"peginterferon alfa\"], [\"ribavirin\"], [\"oseltamivir\"]], \"start\": [[128], [147], [162]], \"entity_id\": [\"T19\", \"T20\", \"T22\"]}}]}, \"Subject\": {\"text\": [[\"a patient with chronic hepatitis C infection\"]], \"start\": [[22]], \"entity_id\": [\"T13\"]}}"
}
]
}
] |
8641617_3 | Both patients were then treated with a carboplatin alternative to cisplatin in the following courses, which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"resulted\"]], \"start\": [[108]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"Both patients\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"carboplatin\"]], \"start\": [[39]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"carboplatin\"]], \"start\": [[39]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"colitis\", \"malignancies\"]], \"start\": [[145, 177]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"neither a relapse of the colitis nor a recurrence of the malignancies\"]], \"start\": [[120]], \"entity_id\": [\"T9\"]}, \"Negated\": {\"text\": [[\"neither\"]], \"start\": [[120]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
18344455_2 | It is rare to develop simultaneous toxicities while on anticonvulsants. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"develop\"]], \"start\": [[14]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"toxicities\"]], \"start\": [[35]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"anticonvulsants\"]], \"start\": [[55]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"anticonvulsants\"]], \"start\": [[55]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
16211208_1 | Because of serious side effects of an increase in the QT interval causing torsades de pointes, dofetilide must be initiated with close monitoring of the QT interval in an inpatient setting. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"increase\"]], \"start\": [[38]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"dofetilide\"]], \"start\": [[95]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"dofetilide\"]], \"start\": [[95]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"QT interval causing torsades de pointes\"]], \"start\": [[54]], \"entity_id\": [\"T7\"]}, \"Severity\": {\"text\": [[\"serious\"]], \"start\": [[11]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
8651254_2 | It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy, including M-CSF, whereas the bone marrow still remained completely remitted. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[79]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"nephrotic syndrome\", \"the bone marrow still remained completely remitted\"]], \"start\": [[47, 138]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"chemotherapy, including M-CSF\"]], \"start\": [[99]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"M-CSF\"]], \"start\": [[123]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
8604715_4 | We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complained\"]], \"start\": [[118]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a patient with human immunodeficiency virus infection\"]], \"start\": [[11]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"human immunodeficiency virus infection\"]], \"start\": [[26]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"foscarnet\"]], \"start\": [[86]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"CMV retinitis\"]], \"start\": [[100]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"foscarnet\"]], \"start\": [[86]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"thirst and polyuria\"]], \"start\": [[132]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
8672829_6 | This represents the first report of nonconvulsive status epilepticus induced by ifosfamide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[69]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"nonconvulsive status epilepticus\"]], \"start\": [[36]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"ifosfamide\"]], \"start\": [[80]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"ifosfamide\"]], \"start\": [[80]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
17536204_2 | BACKGROUND: Headaches have been reported as a potential side effect of capecitabine therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[68]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Headaches\"]], \"start\": [[12]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"capecitabine\"]], \"start\": [[71]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"capecitabine\"]], \"start\": [[71]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
18795_3 | When DSCG was withdrawn, urticaria vanished and the child remained symptom-free. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"remained\"]], \"start\": [[58]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"urticaria vanished\", \"symptom-free\"]], \"start\": [[25, 67]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"DSCG was withdrawn\"]], \"start\": [[5]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"DSCG\"]], \"start\": [[5]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"the child\"]], \"start\": [[48]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"child\"]], \"start\": [[52]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
8345435_1 | Hepatotoxic effects in a child receiving valproate and carnitine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[31]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Hepatotoxic effects\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a child\"]], \"start\": [[23]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"child\"]], \"start\": [[25]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"valproate and carnitine\"]], \"start\": [[41]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"valproate\"], [\"carnitine\"]], \"start\": [[41], [55]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[51]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"valproate\"], [\"carnitine\"]], \"start\": [[41], [55]], \"entity_id\": [\"T9\", \"T10\"]}}]}}"
}
]
}
] |
7718983_5 | We report a case of Graves' hyperthyroidism induced by long-term interferon (IFN) therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[44]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Graves' hyperthyroidism\"]], \"start\": [[20]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[10]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"long-term interferon (IFN) therapy\"]], \"start\": [[55]], \"entity_id\": [\"T7\"], \"Time_elapsed\": {\"text\": [[\"long-term\"]], \"start\": [[55]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"interferon\"]], \"start\": [[65]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
9211543_1 | Bleomycin and cyclophosphamide toxicity simulating metastatic nodules to the lungs in childhood cancer. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"simulating\"]], \"start\": [[40]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Bleomycin and cyclophosphamide toxicity\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"cancer\"]], \"start\": [[96]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"Bleomycin\"], [\"cyclophosphamide\"]], \"start\": [[0], [14]], \"entity_id\": [\"T14\", \"T15\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[10]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"cyclophosphamide\"], [\"Bleomycin\"]], \"start\": [[14], [0]], \"entity_id\": [\"T15\", \"T14\"]}}]}, \"Effect\": {\"text\": [[\"metastatic nodules to the lungs\"]], \"start\": [[51]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"childhood cancer\"]], \"start\": [[86]], \"entity_id\": [\"T11\"], \"Age\": {\"text\": [[\"childhood\"]], \"start\": [[86]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
17266059_1 | The patient presented with fulminant microangiopathic hemolytic anemia and thrombocytopenia within 48 hr of initiating therapy with trimethoprim-sulfamethoxazole. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[12]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"The patient\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"fulminant microangiopathic hemolytic anemia and thrombocytopenia\"]], \"start\": [[27]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"within 48 hr of initiating therapy with trimethoprim-sulfamethoxazole\"]], \"start\": [[92]], \"entity_id\": [\"T8\"], \"Time_elapsed\": {\"text\": [[\"48 hr\"]], \"start\": [[99]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"trimethoprim\"], [\"sulfamethoxazole\"]], \"start\": [[132], [145]], \"entity_id\": [\"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"-\"]], \"start\": [[144]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"trimethoprim\"], [\"sulfamethoxazole\"]], \"start\": [[132], [145]], \"entity_id\": [\"T12\", \"T13\"]}}]}}"
}
]
}
] |
1792646_2 | Pneumocystis pneumonia should be considered in asthmatic patients taking methotrexate who present with fever, pulmonary infiltrates, and hypoxia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"taking\"]], \"start\": [[66]], \"entity_id\": [\"T11\"]}, \"Effect\": {\"text\": [[\"Pneumocystis pneumonia\", \"fever, pulmonary infiltrates, and hypoxia\"]], \"start\": [[0, 103]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"methotrexate\"]], \"start\": [[73]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[73]], \"entity_id\": [\"T15\"]}, \"Disorder\": {\"text\": [[\"asthmatic\"]], \"start\": [[47]], \"entity_id\": [\"T16\"]}}, \"Subject\": {\"text\": [[\"asthmatic patients\"]], \"start\": [[47]], \"entity_id\": [\"T12\"]}, \"Speculated\": {\"text\": [[\"should\"]], \"start\": [[23]], \"entity_id\": [\"T14\"], \"value\": true}}"
}
]
}
] |
16298824_1 | Acute respiratory distress syndrome after rituximab infusion. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[36]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Acute respiratory distress syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"rituximab infusion\"]], \"start\": [[42]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"rituximab\"]], \"start\": [[42]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"infusion\"]], \"start\": [[52]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
17406804_3 | CONCLUSION: Gemcitabine-induced recall pneumonitis is a rarely reported phenomenon and should be taken into account even after extended time interval to the previous radiotherapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[24]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Gemcitabine\"]], \"start\": [[12]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Gemcitabine\"]], \"start\": [[12]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"recall pneumonitis\"]], \"start\": [[32]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |